Abnormal rectal endocrine cells in patients with irritable bowel syndrome

Regulatory Peptides

Volumn 188, Issue , 2014, Pages 60-65

  El Salhy, Magdy ^a,c   Gundersen, Doris ^b   Hatlebakk, Jan G ^c   Gilja, Odd Helge ^c,d   Hausken, Trygve ^c  

^a Stord Helse Fonna Hospital   (Norway)

^b Department of Research ^*  (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Computerised image analysis; Enteroglucagon; PYY; Rectum; Serotonin; Somatostatin

Indexed keywords

OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; SEROTONIN; SOMATOSTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; ENTEROENDOCRINE CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IRRITABLE COLON; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECTUM BIOPSY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SOMATOSTATIN CELL;

COMPUTERISED IMAGE ANALYSIS; ENTEROGLUCAGON; PYY; RECTUM; SEROTONIN; SOMATOSTATIN;

ADOLESCENT; ADULT; CELL COUNT; ENDOCRINE CELLS; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OXYNTOMODULIN; PEPTIDE YY; RECTUM; ROC CURVE; SEROTONIN; SOMATOSTATIN; YOUNG ADULT;

EID: 84891773857     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.11.005     Document Type: Article

References (49)

1. Thompson W.G. A world view of IBS. Irritable bowel syndrome: diagnosis and treatment 2002, 17-26. Saunders, Philadelphia and London. M. Camilleri, R.C. Spiller (Eds.).
2. Drossman D.A., Li Z., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., Whitehead W.E., Janssens J., Funch-Jensen P., Corazziari E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38:1569-1580.
3. El-Salhy M., Gundersen D., Hatlebakk J.G., Hausken T. Irritable bowel syndrome: diagnosis, pathogenesis and treatment options 2012, Nova Science Publishers, Inc., New York.
4. El-Salhy M., Gundersen D., Hatlebakk J.G., Hausken T. Chromogranin a cell density as a diagnostic marker for lymphocytic colitis. Dig Dis Sci 2012, 57:3154-3159.
5. El-Salhy M., Lomholt-Beck B., Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2010, 45:1435-1439.
6. El-Salhy M., Gundersen D., Ostgaard H., Lomholt-Beck B., Hatlebakk J.G., Hausken T. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci 2012, 57:873-878.
7. Sandstrom O., El-Salhy M. Human rectal endocrine cells and aging. Mech Ageing Dev 1999, 108:219-226.
8. Sjolund K., Sanden G., Hakanson R., Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983, 85:1120-1130.
9. El-Salhy M., Mazzawi T., Gundersen D., Hausken T. Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep 2012, 6:1223-1225.
10. Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
11. Dunlop S.P., Jenkins D., Spiller R.C. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98:1578-1583.
12. Lee K.J., Kim Y.B., Kim J.H., Kwon H.C., Kim D.K., Cho S.W. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008, 23:1689-1694.
13. Kim H.S., Lim J.H., Park H., Lee S.I. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3years after acute Shigella infection-an observation in a small case control study. Yonsei Med J 2010, 51:45-51.
14. Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., Crowell M.D., Sharkey K.A., Gershon M.D., Mawe G.M., Moses P.L. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657-1664.
15. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
16. El-Salhy M., Stenling R., Grimelius L. Peptidergic innervation and endocrine cells in the human liver. Scand J Gastroenterol 1993, 28:809-815.
17. El-Salhy M., Sandstrom O., Nasstrom E., Mustajbasic M., Zachrisson S. Application of computer image analysis in endocrine cell quantification. Histochem J 1997, 29:249-256.
18. Sandstrom O., El-Salhy M. Ageing and endocrine cells of human duodenum. Mech Ageing Dev 1999, 108:39-48.
19. Sanstrom O. Age-related changes in the neuroendocrine system of the gut: a possible role in the pathogenesis of gastrointestinal diorders in the elderly. Public Health and Clinical Medicine 1999, 46. Umeå University, Uneå.
20. Cetin Y., Muller-Koppel L., Aunis D., Bader M.F., Grube D. Chromogranin A (CgA) in the gastro-entero-pancreatic (GEP) endocrine system. II. CgA in mammalian entero-endocrine cells. Histochemistry 1989, 92:265-275.
21. Drossman D.A., Morris C.B., Hu Y., Toner B.B., Diamant N., Leserman J., Shetzline M., Dalton C., Bangdiwala S.I. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005, 128:580-589.
22. Mearin F., Balboa A., Badia X., Baro E., Caldwell E., Cucala M., Diaz-Rubio M., Fueyo A., Ponce J., Roset M., Talley N.J. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003, 15:165-172.
23. Mearin F., Baro E., Roset M., Badia X., Zarate N., Perez I. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol 2004, 99:113-121.
24. Ford A.C., Forman D., Bailey A.G., Axon A.T., Moayyedi P. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther 2008, 28:1013-1020.
25. Drossman D.A. The functional gastrointestinal disorders and the Rome II process. Gut 1999, 45(Suppl. 2):II1-II5.
26. Lin O.S. Colonoscopy in irritable bowel syndrome: whom are we reassuring?. Gastrointest Endosc 2005, 62:900-902.
27. Spiller R.C. Potential biomarkers. Gastroenterol Clin North Am 2011, 40:121-139.
28. Barbara G., Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. Gut 2009, 58:1571-1575.
29. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012, 18:5151-5163.
30. El-Salhy M., Gilja O.H., Gundersen D., Hatlebakk J.G., Hausken T. Duodenal chromogranin A cell density as a biomarker for the diagnosis of irritable bowel syndrome. World J Gastroenterol 2013, [in press].
31. El-Salhy M., Vaali K., Dizdar V., Hausken T. Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci 2010, 55:3508-3513.
32. Ali-Rachedi A., Varndell I.M., Adrian T.E., Gapp D.A., Van Noorden S., Bloom S.R., Polak J.M. Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 1984, 80:487-491.
33. Bottcher G., Alumets J., Hakanson R., Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986, 13:283-291.
34. Bottcher G., Sjolund K., Ekblad E., Hakanson R., Schwartz T.W., Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept 1984, 8:261-266.
35. Nilsson O., Bilchik A.J., Goldenring J.R., Ballantyne G.H., Adrian T.E., Modlin I.M. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 1991, 129:139-148.
36. El-Salhy M., Lillebo E., Reinemo A., Salmelid L. Ghrelin in patients with irritable bowel syndrome. Int J Mol Med 2009, 23:703-707.
37. Sjolund K., Ekman R., Wierup N. Covariation of plasma ghrelin and motilin in irritable bowel syndrome. Peptides 2010, 31:1109-1112.
38. Dizdar V., Spiller R., Singh G., Hanevik K., Gilja O.H., El-Salhy M., Hausken T. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2010, 31:883-891.
39. El-Salhy M., Seim I., Chopin L., Gundersen D., Hatlebakk J.G., Hausken T. Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012, 4:2783-2800.
40. Walsh J.H. Gastrointestinal hormones. Physiology of gastrointestinal tract 1994, 1-128. Raven Press, New York. C.J. Jacobson, J. Walsh (Eds.).
41. Goumain M., Voisin T., Lorinet A.M., Ducroc R., Tsocas A., Roze C., Rouet-Benzineb P., Herzog H., Balasubramaniam A., Laburthe M. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol 2001, 60:124-134.
42. Souli A., Chariot J., Voisin T., Presset O., Tsocas A., Balasubramaniam A., Laburthe M., Roze C. Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides 1997, 18:551-557.
43. Whang E.E., Hines O.J., Reeve J.R., Grandt D., Moser J.A., Bilchik A.J., Zinner M.J., McFadden D.W., Ashley S.W. Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci 1997, 42:1121-1127.
44. Dubrasquet M., Bataille D., Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 1982, 2:391-395.
45. Dubrasquet M., Roze C., Ling N., Florencio H. Inhibition of gastric and pancreatic secretions by cerebroventricular injections of gastrin-releasing peptide and bombesin in rats. Regul Pept 1982, 3:105-112.
46. Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989, 34:1411-1419.
47. Schjoldager B.T., Baldissera F.G., Mortensen P.E., Holst J.J., Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 1988, 18:499-503.
48. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., Ghatei M.A., Bloom S.R. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004, 145:2687-2695.
49. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., Wren A.M., Frost G.S., Meeran K., Ghatei M.A., Bloom S.R. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54:2390-2395.